![Sample our Behavioral Sciences journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/110801/TOC-Subject-Sample-2021-Behavioral-Sciences.jpg"})
Abstract
Introduction. The present case study is an analysis of the effect of compression socks on hemostatic activation following a marathon in a female endurance athlete found to be heterozygous for the coagulation factor V (F5 1691 G>A [Arg>Gln rs6025/560]) risk allele that predisposes one to a genetically inherited disorder of blood clotting, Factor V Leiden. Methods. Markers for coagulation and fibrinolysis were obtained 24 h prior to (PRE), immediately after (FINISH) and 24 h after (POST) completion of two marathons: the first in which the runner was not wearing compression socks, and the second in which the runner wore compression socks throughout the race. Results. Compression socks worn during a marathon appeared to lower the overall impact on hemostasis as well as clot formation in this particular athlete as evidenced by lower t-PA (–56%), TAT (–63%) and D-dimer (–30%). Conclusions. Hemostatic activation may be lower with the use of compression socks, and thus may be effective for preserving hemostasis in endurance athletes at risk.
Acknowledgements
The original studies were funded by Hartford Hospital and the American College of Sports Medicine. The authors gratefully acknowledge the research assistance provided by K Ballard, G Panza, L Lorson, J Capizzi, B Foxen and W Roman; the logistical support provided by Beth Shluger at the Hartford Marathon Foundation; and the medical and logistical support provided by Pierre D’Hemecourt, MD at the Boston Athletic Association.
Declaration of interest
PD Thompson is a consultant for AstraZeneca International, Merck & Company, Inc., The Schering-Plough Corporation, Takeda Pharmaceutical Company Limited, Roche and Genomas and is a member of the speaker’s bureau for Merck & Company, Inc., Pfizer, Inc., Abbott Labs and AstraZeneca International. BA Taylor received honorarium from Amgen Pharmaceutical for consultation services for pharmacovigilance monitoring board. The original study received a product sponsorship provided by 2XU Compression Socks. The results of the present study do not constitute endorsement by ACSM. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.